GLPMGRVictoza injection sites and dose steps: what the manufacturer says
This page lists where the manufacturer says Victoza (liraglutide) can be injected in the UK, the EU and the US, and its dose steps and missed-dose wording, in their own words, with the documents each comes from. It is not medical advice.
Talk to a healthcare professional. The injection areas shown come from the manufacturer's product information, and the shading shows where you've injected before. GLPMGR is not a medical device and this is not medical advice: it can't tell you where it is safe for you to inject. Talk to your doctor, pharmacist or nurse about where and how to inject, follow the instructions from your prescriber and the leaflet supplied with your medicine, and ask a healthcare professional if you are unsure, or if you have pain, lumps, bruising or any other problem at an injection site.
Where Victoza can be injected
Manufacturer: Novo Nordisk
United Kingdom
Areas listed:
- Front of waist (abdomen)
- Front of thigh
- Upper arm
Rotation, in the manufacturer’s words: “Change the place where you inject each day to reduce the risk of developing lumps.”
Source: MHRA products database / Abacus Medicine Ltd: Victoza 6 mg/ml solution for injection in pre-filled pen, package leaflet (PL 45763/1340, last revised 11/02/2025), revised 11/02/2025. Checked 20 September 2026.
Also consulted:
- MHRA products database / Novo Nordisk A/S: Victoza 6 mg/ml solution for injection in pre-filled pen, Summary of Product Characteristics (PLGB 04668/0413, text revised 04/11/2024) — Lists the same three areas; no rotation wording.
- MHRA products database / Orifarm UK Ltd: Victoza 6 mg/ml pre-filled pen, package leaflet (PLGB 45985/0233, revision 16/10/2023) — An older parallel-import leaflet giving the same areas; no rotation sentence.
European Union
Areas listed:
- Abdomen
- Thigh
- Upper arm
Rotation, in the manufacturer’s words: “Change the place where you inject each day to reduce the risk of developing lumps.”
Source: EMA: Victoza EPAR Product Information (English). Checked 20 September 2026.
Also consulted:
- EMA: Victoza: EPAR (European Public Assessment Report) page, listing the current product information and its last-updated date — Used to confirm the current English product information.
United States
Areas listed:
- Stomach (abdomen)
- Thigh
- Upper arm — another person should inject here
Rotation, in the manufacturer’s words: “Change (rotate) your injection site with each injection. Change (rotate) your injection sites within the area you choose for each dose.”
Source: FDA / DailyMed: Victoza prescribing information and patient instructions (DailyMed, current label), revised v31 (2025-10-14). Checked 20 September 2026.
Also consulted:
- Novo Nordisk: How to take Victoza (patient website, step by step) — Consumer summary; lists the same three areas but not the caregiver rule for the upper arm, so the full label is followed.
Victoza dose steps and missed doses
Most GLP-1 medicines start low and step up, which doctors call titration. This is what the Victoza product information says, quoted word for word. UK wording comes from the patient leaflet; US wording from the prescribing information and Medication Guide. Your prescriber’s instructions come first, and GLPMGR never works out or recommends a dose.
United Kingdom
Dose steps, in the product information’s words:
- “The starting dose is 0.6 mg once a day, for at least one week.”
- “Your doctor will tell you when to increase it to 1.2 mg once a day.”
- “Your doctor may tell you to further increase the dose to 1.8 mg once a day, if your blood glucose is not adequately controlled with a dose of 1.2 mg.”
- “Do not change your dose unless your doctor has told you to.”
If a dose is missed:
- “If you forget a dose, use Victoza as soon as you remember. However, if it is more than 12 hours since you should have used Victoza, skip the missed dose. Then take your next dose as usual the following day.”
- “Do not take an extra dose or increase the dose on the following day to make up for the missed dose.”
Source: MHRA / Novo Nordisk: Victoza 6 mg/ml pre-filled pen package leaflet, revised 11/02/2025. Checked 27 September 2026.
United States
Dose steps, in the product information’s words:
- “The recommended starting dosage of VICTOZA is 0.6 mg injected subcutaneously once daily for one week.”
- “After one week at the 0.6 mg once daily dosage, increase the dosage to 1.2 mg injected subcutaneously once daily.”
- “If additional glycemic control is required, increase the dosage to the maximum recommended dosage of 1.8 mg injected subcutaneously once daily after at least one week of treatment with the 1.2 mg once daily dosage.”
If a dose is missed:
- “If you miss a dose of VICTOZA, take the missed dose at the next scheduled dose. Do not take 2 doses of VICTOZA at the same time.”
- “Instruct patients who miss a dose of VICTOZA to resume the once daily dosage regimen as prescribed with the next scheduled dose. Do not administer an extra dose or increase the dose to make up for the missed dose.”
Using it with another GLP-1 medicine: “Coadministration with other liraglutide-containing products is not recommended.”
Source: FDA / Novo Nordisk: Victoza prescribing information and Medication Guide, DailyMed, effective 10/2025. Checked 27 September 2026.
In GLPMGR, enter the dose steps your prescriber gave you and it fills in the right dose each time you log. The same wording is in the app, under Dose Steps & Missed Doses.
Track your Victoza doses and injection sites in GLPMGR
GLPMGR is a private GLP-1 tracker for iPhone, iPad and Apple Watch. Choose Victoza when you record a dose and it offers only the areas above for your region, shows a body map of where you have injected before, and shows the manufacturer’s rotation wording. It also follows your dose steps, reminds you when a dose is due, and keeps a note of side effects. It does not tell you where to inject, and it is independent of Novo Nordisk.
Other medicines with the same active ingredient:
Medical disclaimer
Talk to a healthcare professional. The injection areas shown come from the manufacturer's product information, and the shading shows where you've injected before. GLPMGR is not a medical device and this is not medical advice: it can't tell you where it is safe for you to inject. Talk to your doctor, pharmacist or nurse about where and how to inject, follow the instructions from your prescriber and the leaflet supplied with your medicine, and ask a healthcare professional if you are unsure, or if you have pain, lumps, bruising or any other problem at an injection site.